Chronic Liver Disease Foundation

Join Pierre Gholam, MD, for Major Advancements in MASH Management streaming live on November 15th at 7:00 PM ET from the Gastro Health Updates in GI Conference. This complimentary symposium is tailored to healthcare professionals managing and treating MASH. Register now at https://loom.ly/sEZKwFg!

Join Dr. Marcelo Kugelmas, MD, Kimberly Brown, MD, and Christina J. Hanson, FNP for our Breakthroughs in MASH Diagnosis and Management Meeting! Designed for gastroenterologists, hepatologists, NPs, and PAs, this event offers valuable insights to improve your MASH management skills. Don't miss out! Register at https://loom.ly/nPmq_DI.

Join us for Innovations in the Management of MASH on Tuesday, October 29, at 6:30 PM, featuring Dr. Rohit Satoskar at Clyde's at Mark Center in Alexandria. Attendees can earn up to 1.5 AMA PRA Category 1 Credits™. Registration is complimentary. REGISTER NOW at https://loom.ly/rc3w4bM ! Brian Lam Zobair Younossi

Join us in Durham, North Carolina, for an Innovations in the Management of MASH meeting with Kara Wegermann, MD! Earn up to 1.5 AMA PRA Category 1 Credits™. Registration is complimentary. Learn more and register at https://loom.ly/rc3w4bM!

Join us for Innovations in the Management of MASH on Tuesday, October 29, at 6:30 PM, featuring Dr. Rohit Satoskar at Clyde's at Mark Center in Alexandria. Attendees can earn up to 1.5 AMA PRA Category 1 Credits™. Registration is complimentary. REGISTER NOW at https://loom.ly/rc3w4bM ! Brian Lam Zobair Younossi

The Innovations in the Management of MASH meeting series is designed for those managing and treating patients with MASH! To view meetings near you and register visit https://loom.ly/Ohq-xHY.

Join us in Pasadena! Next month, Dr. sammy saab, Dr. Mazen Noureddin, MD, MHSc, and Dr. Norah Terrault will lead the Breakthroughs in MASH Diagnosis and Management at the Liver Connect City Series Meeting. Stay ahead in liver health advancements and earn CME credits!

An excellent overview of MASLD and MASH by NIKOLAOS PYRSOPOULOS from NYU Langone Health who shared many insights this morning, hosted by Global NASH Council and the Chronic Liver Disease Foundation about "MAJOR ADVANCEMENT IN MASH MANAGEMENT". In part 1, let's dive into the incidence aspect of the MASLD/MASH component of today's presentation. The global burden of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and its advanced form, Metabolic dysfunction-Associated Steatohepatitis (MASH), is on the rise, affecting up to 40% of the population in some regions. Driven by the increasing prevalence of metabolic disorders such as obesity and type 2 diabetes, MASLD has become one of the most common liver diseases worldwide. With nearly 70% of type 2 diabetes patients now affected and concerning rates in pediatric populations, urgent action is needed. Early diagnosis, lifestyle interventions, and innovative therapies are crucial to manage this growing public health challenge and prevent severe outcomes like cirrhosis and liver-related mortality. 5 Key Takeaways: 1. Rising Prevalence: MASLD now affects up to 40% of the population in some regions, with significant increases since the 1990s. 2. Impact on Children: Pediatric MASLD is growing, with 25% of children in Latin America affected, highlighting the importance of early intervention. 3. Link to Type 2 Diabetes: 65-70% of patients with type 2 diabetes also have MASLD, making this a high-risk group for liver disease progression. 4. Need for Early Diagnosis: Non-invasive tests like FIB-4 and transient elastography are critical for identifying patients at risk of advancing to MASH. 5. Future Outlook: Without targeted interventions, both MASLD and MASH will continue to rise, underscoring the need for lifestyle changes and new treatment options. Supported by an educational grant from Madrigal Pharmaceuticals. American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Canadian Association for the Study of the Liver, Global Liver Institute, European Liver Patients' Association - ELPA, Barcelona Institute for Global Health (ISGlobal), Christopher Kopka, Paul Brennan, Jeffrey V. Lazarus, Prof. Shira Zelber Sagi, Jörn M. Schattenberg, Zobair Younossi, Surfing MASH, Madrigal Pharmaceuticals, Siemens Healthineers, Novo Nordisk Written in collaboration with CHATGPT40

If you haven't already, join Dr. Kim Brown and Dr. Steven Flamm on this CLDF KOL Conversation as they explore the evolving treatment landscape for fatty liver disease, focusing on new and emerging therapies for MASLD. Tune in to the full podcast here: https://loom.ly/mpoAeUA

Exciting News! The Liver Connect City Series is coming to San Francisco! Join Dr. Robert Wong, Dr. Marina Roytman, and Dr. Edward Holt for expert insights on MASH. Don’t miss this educational event—Register now at https://loom.ly/a5ghb70.